US FDA approves lisocabtagene maraleucel (Breyanzi) for treatment of relapsed or refractory large B-cell lymphoma

Lisocabtagene maraleucel, a chimeric antigen receptor (CAR) T cell therapy, was specifically approved for use after failure of two prior lines of treatment. Aproval was based on a multicentre clinical trial of > 250 adults which demonstrated a complete remission rate of 54%.

Source:

FDA